MARKET

INCY

INCY

Incyte Corp
NASDAQ
94.99
-2.65
-2.71%
Opening 11:44 05/15 EDT
OPEN
97.44
PREV CLOSE
97.63
HIGH
97.70
LOW
94.82
VOLUME
409.79K
TURNOVER
--
52 WEEK HIGH
112.29
52 WEEK LOW
59.15
MARKET CAP
18.98B
P/E (TTM)
13.43
1D
5D
1M
3M
1Y
5Y
1D
Bank of America Securities Remains a Buy on Incyte (INCY)
TipRanks · 1d ago
Wells Fargo Remains a Hold on Incyte (INCY)
TipRanks · 2d ago
Analysts Conflicted on These Healthcare Names: Incyte (INCY), Pacific Edge Limited (OtherPFGTF) and Mach7 Technologies (OtherTDMMF)
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Dyne Therapeutics (DYN)
TipRanks · 3d ago
Incyte frontMIND Phase 3 study backs tafasitamab filing in first-line DLBCL
PUBT · 3d ago
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
Barchart · 3d ago
Weekly Report: what happened at INCY last week (0504-0508)?
Weekly Report · 4d ago
Impressive Earnings May Not Tell The Whole Story For Incyte (NASDAQ:INCY)
Simply Wall St · 5d ago
More
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.

Webull offers Incyte Corp stock information, including NASDAQ: INCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INCY stock methods without spending real money on the virtual paper trading platform.